Table of Contents:

1)        Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018
1a) IDO & TDO Inhibitors

1b) TGF-beta Inhibitors

1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors

1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists

1e) CSF-1R Antagonists & CSF-1 Inhibitors

1f) CD47 Antagonists & SIRPalpha Inhibitors

1g) Adenosine Pathway Modulation

1h) STING Agonists

2)        Corporate Tumor Microenvironment Modulator R&D Pipelines